The FDA cleared an investigational new drug application for a phase 2 trial of GRF312 ophthalmic solution, an immunoglobulin ...

Clearance of ASC50 paves the way for a Phase I trial in patients with mild-to-moderate plaque psoriasis.

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

Prices of newly launched drugs in the U.S. have more than doubled from 2021 to 2024, driven by rare disease therapies, ...

SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the ...

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The US Food and Drug Administration (FDA) has cleared Grifols' investigational new drug (IND) application to initiate a Phase ...

The initiatives reflect the latest measures from federal agencies to reduce and ultimately replace animal testing in drug development and ...

Satsuma, a unit of a Japanese drugmaker with U.S. headquarters in Durham, said its treatment, called Atzumi, received its new ...

The announcement, which followed the FDA setting new guidelines on COVID vaccine approvals, erased the stock’s gains from ...

COVID-19 shots for healthy younger adults and children will no longer be routinely approved under a major new policy shift unveiled Tuesday by the Trump administration.